Moderna swung to profit in Q3 2026, driven by strong international COVID-19 vaccine sales and partnership payments, and raised its full-year revenue guidance. The company also highlighted momentum for its mRNA-based cancer vaccine pipeline.
A new study found that patients with autoimmune rheumatic disease who received updated or booster COVID-19 vaccines had significantly lower odds of COVID-related hospitalization compared to those who only received the initial vaccine series. The findings come as COVID hospitalizations have risen sharply in recent weeks.
The CDC removed a webpage supporting Covid-19 vaccines for people preparing to have a baby following backlash from critics including Jeffrey Tucker of the Brownstone Institute and Joseph Marine. The page now redirects to interim clinical considerations.
Health Secretary Robert F. Kennedy Jr. has hired an Army doctor who opposed Covid vaccines to investigate whether the shots caused the deaths of approximately 2,500 military service members. The investigation comes as Covid vaccine uptake rates among adults have continued to decline during the Trump presidency.
Otsuka announced two-year Phase 3 VISIONARY trial results showing VOYXACT (sibeprenlimab-szsi) stabilized kidney function decline in IgA nephropathy patients, with annual eGFR slope of +0.3 versus -4.2 for placebo. Separately, BioNTech lowered its 2026 revenue guidance by €400 million to €1.6-1.9 billion due to declining COVID-19 vaccine demand.
Scientists discovered that mRNA cancer vaccines can still destroy tumors even when a key immune cell type is missing, revealing unexpected mechanisms of action. The research advances understanding of how Nobel Prize-winning mRNA technology can be adapted from COVID-19 vaccines to fight cancer.